phase i study of u3-1287, a fully human anti-her3 monoclonal...
TRANSCRIPT
1
Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients
With Advanced Solid Tumors
Patricia LoRusso1, Pasi A. Jänne2, Moacyr Oliveira3, Naiyer Rizvi4, Lisa Malburg1, Vicki
Keedy5, Lorrin Yee6, Catherine Copigneaux7, Thore Hettmann8, Chi-Yuan Wu9, Agnes Ang9,
Abdel-Baset Halim7, Robert A. Beckman7, Darrin Beaupre9, and Jordan Berlin5
1 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan; 2 Dana-Farber Cancer
Institute, Boston, Massachusetts; 3 Northwest Medical Specialties, Tacoma, Washington; 4
Memorial Sloan-Kettering Cancer Center, New York, New York; 5 Vanderbilt University
Medical Center, Nashville, Tennessee; 6Vista Oncology, Olympia, Washington; 7 Daiichi
Sankyo Pharma Development, Edison, New Jersey; 8 U3 Pharma GmbH, Munich, Germany; and
9 Amgen Inc., Thousand Oaks, California
Running head: Phase I Study of U3-1287 in Patients With Advanced Solid Tumors
Keywords: HER3, U3-1287
Acknowledgment of research support: The study was sponsored by Daiichi Sankyo
Pharmaceutical Development and Amgen, Inc.
Corresponding author: Patricia M. LoRusso, Karmanos Cancer Institute, 4100 John R St.,
Detroit, MI 48201; phone: 313-576-8716; fax: 313-576-8719; e-mail: [email protected].
Conflict of interest disclosure: Darren Beaupre, Chi-Yuan Wu, and Agnes Ang are employed by
and own stock in Amgen, Inc. Thore Hettmann is an employee of U3 Pharma. Abdel Halim,
Robert Beckman, and Catherine Copigneaux are employees of Daiichi Sankyo Pharmaceutical
Development, and Robert Beckman and Catherine Copigneaux own stock in Daiichi Sankyo
Pharmaceutical Development. Jordan Berlin has served as a consultant to Amgen and received
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
2
research funding from Amgen, Inc. Vicki Keedy has received research funding from Daiichi
Sankyo Pharmaceutical Development and Amgen, Inc. Patricia LoRusso has received research
funding from U3 Pharma. Lisa Malburg, Naiyer Rizvi, Lorrin Yee, and Moacyr Oliveria have
no conflicts of interest to disclose.
Word count:
Abstract: 236
Text, excluding references: 3374
Figures: 3
Tables: 3
Previously published, in part, in:
LoRusso P, Keedy V, Yee L, et al: A phase 1, open-label, dose-finding study to assess the
safety and tolerability of U3 1287 (AMG 888), a human monoclonal antibody targeting HER3
in patients with advanced solid tumors. Presented as a poster at EORTC-NCI-AACR 2010 and
published as an abstract in Eur J Cancer 8:76, 2010 (suppl; abtr 234)
Berlin J, Keedy VL, Janne PA, et al: A first-in-human phase I study of U3-1287 (AMG 888), a
HER3 inhibitor, in patients (pts) with advanced solid tumors. Presented as a poster at ASCO
2011 and published as an abstract in J Clin Oncol 29:200s, 2011 (suppl; abstr 3026)
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
3
Translational Relevance
Agents targeting human epidermal growth factor 1 (HER/EGFR) and 2 (HER2) have been of
intense interest, but their efficacy in the clinic has been confined to subsets of patients. Research
indicates that the related protein HER3 is important in tumorigenesis, as it activates oncogenic
signaling pathways, is upregulated in many solid tumors, and is associated with poor prognosis
in cancer patients. Although devoid of kinase activity itself, HER3 is recognized as a key
dimerization partner for other HER family members, and HER3:HER2 heterodimers
demonstrate particularly potent mitogenic signaling. However, therapeutic inhibition of HER3
has not previously been clinically evaluated. We present results from the first-in-human study of
U3-1287, a first-in-class HER3-targeting monoclonal antibody. Therapy with U3-1287 was well
tolerated and resulted in stable disease and tumor reductions in some patients. Our study lays
the foundation for further research into U3-1287 and HER3 inhibition for the treatment of solid
tumors.
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
4
ABSTRACT
Purpose: Human epidermal growth factor receptor 3 (HER3) is a key dimerization partner for
other HER family members, and its expression is associated with poor prognosis. This first-in-
human study of U3-1287 (NCT00730470), a fully human anti-HER3 monoclonal antibody,
evaluated its safety, tolerability, and pharmacokinetics (PKs) in advanced solid tumor patients.
Experimental Design: The study was conducted in 2 parts: part 1—sequential cohorts received
escalating doses (0.3–20 mg/kg) of U3-1287 every 2 weeks (q2w), starting 3 weeks after the
first dose; part 2—additional patients received 9, 14, or 20 mg/kg U3-1287 q2w, based on
observed tolerability and PKs from part 1. Recommended phase II dose, adverse event (AE)
rates, PKs, and tumor response were determined.
Results: Fifty-seven patients (part 1: 26; part 2: 31) received U3-1287. As no dose-limiting
toxicities were reported, the maximum tolerated dose was not reached. The maximum
administered dose was 20 mg/kg q2w. The most frequent AEs related to U3-1287 were fatigue
(21.1%), diarrhea (12.3%), nausea (10.5%), decreased appetite (7.0%), and dysgeusia (5.3%).
No patient developed anti–U3-1287 antibodies. In these heavily pretreated patients, stable
disease was maintained ≥ 9 weeks in 19.2% in part 1 and ≥ 10 weeks in 25.8% in part 2.
Conclusion: U3-1287 treatment was well tolerated, and some evidence of disease stabilization
was observed. PK data support U3-1287 dosing of 9 to 20 mg/kg every 2 to 3 weeks.
Combination studies of U3-1287 are ongoing.
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
5
INTRODUCTION
The human epidermal growth factor receptor (EGFR/HER) family of receptor tyrosine kinases,
consisting of HER1 (EGFR), HER2, HER3, and HER4, plays an important role in oncogenesis.
By homodimerizing and heterodimerizing, HER family members activate signaling pathways
that are involved in cellular processes, including morphogenesis, proliferation, angiogenesis,
and survival.(1–4) A number of tumor types require EGFR or HER2 signaling for growth and
survival,(5–7) prompting the development of various therapeutic agents that target the EGFR
and HER2 receptors. Current anti-EGFR and anti-HER2 agents, however, have proven to be
effective only in a subset of patients, and initial response is frequently followed by relapse and
the development of therapeutic resistance. Recent studies suggest that HER3 upregulation or
reactivation is important to the development of resistance to EGFR- and HER2-targeted
treatments.(8–11)
Elevated HER3 expression has been detected in many tumor types and is associated with
negative clinical prognosis, including shorter relapse-free survival time in breast cancer (12) and
shorter overall survival times in lung, ovarian, and colon cancers.(13–16) HER3 is also
overexpressed and occasionally amplified in non–small cell lung cancer (NSCLC), and
autocrine loops with its ligands have been documented.(13,17–20) While lacking intrinsic
kinase activity itself,(21,22) HER3 activates signaling pathways through heterodimerization
with other HER family members. HER2:HER3 heterodimers demonstrate particularly potent
mitogenic signaling compared with other HER family heterodimers.(23) Targeting HER3,
therefore, may negatively affect tumors and improve the efficacy of current anti-HER agents.
U3-1287 (NCT00730470) is a first-in-class, fully human monoclonal antibody directed against
HER3. In vitro, U3-1287 binds to the extracellular domain of HER3 and promotes receptor
internalization, inhibiting both basal and ligand-induced receptor signaling.(24–26) Tumor cells
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
6
treated with U3-1287 demonstrate reduced cellular migration, proliferation, and anchorage-
independent growth. In addition, U3-1287 and anti-EGFR antibody treatment of EGFR- and
HER3-expressing xenografts significantly reduced tumor growth compared with anti-EGFR
antibodies alone or with an isotype immunoglobulin (IgG) control in both EGFR wild-type
models and resistant models with the T790M EGFR mutation.(27)
A phase I, open-label, first-in-human study of single-agent U3-1287 was initiated to assess its
safety, tolerability, and pharmacokinetic (PK) profile in patients with advanced solid tumors.
The study was conducted in 2 parts. Part 1 was a dose-escalation, dose-finding study designed
to identify the maximum tolerated dose (MTD) by treating successive cohorts with escalating
doses and evaluating the incidence of dose-limiting toxicities (DLTs). Part 2 was a dose-
expansion phase conducted in patients with advanced malignancies along with an exploratory
NSCLC cohort that further evaluated the safety, tolerability, and efficacy of the possible dose
levels identified from part 1 PK in the intended phase II population. This report describes results
from both parts of this study.
MATERIALS AND METHODS
Patients
For parts 1 and 2, eligible patients had a confirmed diagnosis of an advanced solid tumor that
was refractory to standard treatment or for which no standard therapy existed and that was of a
type known to express HER3. For part 2, the same eligibility criteria were used, but an
exploratory cohort was included in which ≥ 15 of 30 patients enrolled had to have NSCLC.
Patients were not preselected on the basis of RAS or EGFR status. All patients were ≥ 18 years
of age, had an Eastern Cooperative Oncology Group performance status of 0 to 2, and a life
expectancy of > 3 months. Additional inclusion criteria included controlled hypertension
(diastolic ≤ 100 mm Hg; systolic ≤ 140 mm Hg), left ventricular ejection fraction ≥ 50%,
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
7
cumulative anthracycline exposure ≤ 360 mg/m2, and adequate neutrophil count (≥ 1,500/µL),
hemoglobin count (≥ 9 g/dL), platelet count (≥ 100,000/µL), calculated creatinine clearance
level (modified Cockcroft-Gault equation; ≥ 60 mL/min), bilirubin level (≤ 2 × upper limit of
normal [ULN]), prothrombin time or partial prothrombin time (≤ 1.5 × ULN), alkaline
phosphatase level (≤ 2 × ULN with no liver or bone involvement or < 5 × ULN with liver or
bone involvement), and alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
levels (≤ 2.5 × ULN with no liver involvement or < 5 × ULN with liver involvement). Patients
were ineligible if they had previously received an anti-HER3–targeted antibody or if they had
received small molecule tyrosine kinase inhibitors within 2 weeks; major surgery, antibody
therapy, retinoid therapy, hormonal therapy, or therapeutic or palliative radiotherapy within 4
weeks; or nitrosoureas or mitomycin C chemotherapies within 6 weeks of the first dose of U3-
1287. Patients with hematopoietic malignancies, untreated or symptomatic brain metastases, or
known HIV or active hepatitis B or C virus infection were ineligible. The study protocol was
approved by participating institutions' research ethics boards, and each patient signed a consent
form.
Study design and dosing
This was a multicenter study conducted in 2 parts. In part 1, dose escalation followed a
modified 3 + 3 study design: 3 or 4 patients were enrolled initially in sequential cohorts of 0.3,
1, 3, 6, 9, 14, and 20 mg/kg. U3-1287 was administered as an intravenous (IV) infusion over 60
minutes. After the first IV administration of U3-1287 on day 1, a 21-day observation period
occurred for each patient. If no DLTs were observed during the first 21 days, U3-1287
administration began on day 22 and was administered every 14 days. In part 2, the initial dose
for dose expansion was determined on the basis of preliminary safety and PK through cohort 5
(9 mg/kg) from the dose-escalation phase of the study. The dose of 9 mg/kg was the first dose
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
8
that produced a trough drug level 10-fold greater than the trough level that corresponded to
maximal preclinical efficacy. Escalating doses administered in part 2 of the study were 9, 14,
and 20 mg/kg, administered IV on days 1 and 15 of a 28-day cycle.
DLT was defined as drug-related grade 3 or higher hematologic or nonhematologic toxicity
(except alopecia); for fatigue, only grade 3 fatigue that persisted for > 7 days or grade 4 fatigue
of any length were included. For patients with bone or liver metastases and baseline levels ≥ 2.5
× ULN (for alkaline phosphatase > 2 × ULN), DLTs did not include elevations in AST, ALT, or
alkaline phosphatase unless the following criteria were met: AST or ALT > 8 × ULN (if
baseline was 2.5–5 × ULN in patients with liver metastases); alkaline phosphatase > 8 × ULN
(if baseline level was 2–5 × ULN in patients with bone or liver metastases). DLT assessment
followed the guidelines provided in the Common Terminology Criteria for Adverse Events
(CTCAE), v.3.0. MTD was defined as the highest dose with an observed incidence of DLT in
fewer than 33% of the patients in the cohort.
Tumor response and safety
In part 1 of the study, disease response assessment using modified Response Evaluation Criteria
in Solid Tumors (RECIST; 28) was performed at screening, days 35 and 64, and every 8 weeks
thereafter. In part 2 of the study, disease response assessment occurred at screening, days 42 and
70, and every 8 weeks thereafter. 2-deoxy-2-(18F)fluoro-D-glucose positron emission
tomography/computed tomography scans were performed after eligibility was determined and
within 14 days prior to the first dose of study drug (baseline) and on day 42 in part 1 (cohorts 3
through 7) and part 2 (all cohorts), once dose levels that might be pharmacodynamically active
had been achieved. Metabolic response was assessed as described by Young et al.(29)
All adverse events (AEs) were recorded from the time of informed consent until 30 days after
the last dose of U3-1287 and were graded according to CTCAE v.3.0. Scheduled 12-lead
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
9
electrocardiograms were performed during screening at days 1, 15, 29, 57, and every 4 weeks
thereafter. QTc interval was evaluated centrally and corrected for heart rate by the Fridericia’s
formula (QTcF).
PK evaluation
During part 1, PK evaluation was conducted on all patients on day 1 of treatment (blood
samples taken at end of infusion [EOI], and at 3, 6, 24, and 72 hours after EOI), and on days 7,
14, and 21. Samples were also obtained immediately before the third dose (day 36), at EOI, at 3
and 6 hours after EOI, and on days 37, 39, and 42. Preinfusion and EOI PK samples were also
taken on days 22, 50, and 64, and every 8 weeks thereafter. The PK parameters (area under the
plasma concentration-time curve [AUC], maximum observed serum concentration [Cmax], and
half-life [t1/2]) were derived from serum concentration–time data following doses 1 and 3 during
part 1 and then calculated by noncompartmental analysis using WinNonlin® Enterprise v5.1.1
(Pharsight Corp., Mountain View, CA).
Immunogenicity
Blood samples for determining anti–U3-1287 antibodies in serum were collected in part 1
before dosing on day 1 and on day 21, day 64, and every 8 weeks thereafter, as well as during
an end-of-study visit. In part 2, blood samples were collected before dosing on days 1, 29, and
57, and then every 8 weeks and at the end-of-study visit.
HER3 assays
HER3 gene amplification status and protein expression were assessed by fluorescence in situ
hybridization (FISH) and immunohistochemistry (IHC), respectively, in archived, formalin-
fixed, paraffin-embedded (FFPE) tumor tissues. For FISH, tissue sections were evaluated
through incubation with the dual color probe set ZytoLight® SPEC HER3/CEN 12 (Zytovision,
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
10
Bremerhaven, Germany) and scored both by absolute copy number and amplification ratio. For
IHC, tissue sections were incubated with mouse IgG antihuman HER3 (sc81455, Santa Cruz
Biotechnology) and scored as a percentage of positive cells and on a semiquantitative scale
using H-scores for total HER3 in the cytoplasm and membrane. Samples were analyzed by a
single pathologist who was blinded to clinical outcomes.
RESULTS
Patients
Twenty-six patients were enrolled in part 1, and 31 patients were enrolled in part 2.
Demographics and clinical characteristics are summarized in Table 1. The most common
primary tumor sites were colorectal (50.9%) and NSCLC (35.1%); 17 of the 20 patients with
NSCLC were specifically enrolled into the dose-expansion cohorts.
All patients had received chemotherapy, with a median of 5 previous regimens. Forty-one
patients (71.9%) received prior EGFR-targeted therapy, of which 3 patients (7.3%) had partial
response (PR) as a best response to prior EGFR-targeted treatment, 14 patients (34.1%) had a
best response of stable disease (SD), and 16 patients (39.0%) had progressive disease (PD). The
best response on prior EGFR-targeted therapy was unknown for 8 patients (19.5%).
All patients received at least 1 dose of U3-1287. Fifty-two patients (91.2%) withdrew from
study because of disease progression, 2 patients (3.5%) because of full withdrawal of consent
(unrelated to any study-related event), 2 patients (3.5%) because of nonfatal AEs (grade 2
prolonged QTc interval [20 mg/kg] and grade 3 pulmonary embolism [20 mg/kg]), and 1 patient
because of a fatal AE (grade 5 respiratory insufficiency [14 mg/kg]); all were considered
unrelated to U3-1287.
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
11
Safety
Most patients (55 [96.5%]) had at least 1 AE. Approximately half of the patients (47.3%) had
AEs with a highest grade of 1 or 2. The most common AEs overall (≥ 20% of patients) included
fatigue (42.1%), diarrhea (24.6%), nausea (22.8%), and dyspnea (21.1%; Table 2). Based on
this limited sample set, it did not appear that any AEs were dose-dependent. U3-1287–related
AEs were reported in 26 patients (45.6%) and included fatigue (21.1%), diarrhea (12.3%),
nausea (10.5%), decreased appetite (7.0%), and dysgeusia (5.3%). Nearly all drug-related events
were grade 1 or 2; only 1 patient (3 mg/kg) had a drug-related AE that was grade ≥ 3 (a
nonserious grade 3 event of hyponatremia on day 20 and a nonserious grade 3 event of
hypophosphatemia on day 23). Both events were possibly related to study medication. There
were no grade 4 or 5 U3-1287–related AEs.
Overall, 6 patients experienced 7 grade ≥ 4 events; none were related to U3-1287. Nineteen
patients (33.3%) had a serious AE; none were deemed related to U3-1287. Eight patients
discontinued study treatment due to 10 AEs, none of which were judged to be related to
treatment with the study drug.
One patient had asymptomatic grade 2 QTcF prolongation, and 3 female patients had
asymptomatic QTcF between 450 and 470 ms (normal for females). Analysis of QTcF
prolongation as a function of U3-1287 serum concentration showed no concentration
dependence (see Supplementary Fig. S1).
No DLTs were reported for any of the cohorts during the DLT observation window. Thus, the
MTD was not reached and is therefore not lower than the maximum dose administered in this
study (20 mg/kg).
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
12
Pharmacokinetics
PK parameters for dosing cohorts in part 1 are summarized in Table 3. The Cmax and AUC of
U3-1287 increased more than dose-proportionally across the tested range (0.3–20 mg/kg). PK
approached linearity at the higher doses studied (6–20 mg/kg), indicating that saturation of
clearance pathways occurs at doses greater than 6 mg/kg. Mean serum t1/2 was approximately 8
days at doses > 6 mg/kg. Data from PK analysis of part 2 indicate that in patients treated with 9,
14, or 20 mg/kg every 2 weeks (q2w), steady state was achieved after approximately 3 doses. At
dose levels ≥ 9 mg/kg, the mean minimum observed serum concentration (Cmin) beyond the
second dose was at least 10-fold greater than the Cmin associated with maximal efficacy in
mouse xenograft models (90% inhibitory concentration [IC90] ≈ 3 µg/mL; Fig. 1; ref. 30).
Owing to this, as well as the simulation of the q2w and every 3 week (q3w) dosing data, the PK
profile of U3-1287 supports IV administration at or above 9 mg/kg q2w or q3w.
Immunogenicity
No patient developed human antihuman antibodies (HAHAs) after dosing with U3-1287. One
of 26 patients tested during part 1 and 1 of 31 patients tested during part 2 had positive HAHA
results before and after exposure to U3-1287, as detected by immunoassay. No neutralizing
antibodies were detected at any visit for either patient; therefore, the HAHAs detected were
present before dosing and were nonneutralizing.
Efficacy
In the 51 patients evaluable for tumor response, SD at the earliest observation time point was
the best single-evaluation response in 50.9% of patients. In part 1, SD was recorded in 1 or
more evaluations in 53.8% of patients and maintained for at least 16 weeks in 7.7% of patients.
In part 2, SD was recorded in at least 1 evaluation in 48.4% of patients and maintained for at
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
13
least 16 weeks in 16.1% of patients (Fig. 2). Twenty-two patients (38.6%) had PD. No patient
had complete response or PR per modified RECIST. One patient with NSCLC (20 mg/kg) had
tumor shrinkage (26.3% decrease) that approached but did not reach the 30% reduction
threshold for PR (Fig. 3).
The overall metabolic response rate was 3.5%: the previously mentioned NSCLC patient and 1
patient in part 1 (14 mg/kg) had partial metabolic responses. Both patients were nonsmokers
who had received prior EGFR-targeted therapy. The first patient previously had a best response
of SD while receiving erlotinib-based therapy and, in this study, had SD for 42 weeks. The
second patient previously had PD while receiving cetuximab-based therapy and, in this study,
was removed for PD after the first tumor assessment post-therapy; however this patient had SD
per central review that lasted 32 days. No clear dose response could be discerned given the
limited number of responders. Overall in this study, 24.6% of patients had SD, 40.4% had PD,
and 31.6% were not evaluable for metabolic tumor response.
Pharmacodynamic and predictive biomarker evaluations
Expression of HER3 was investigated at the gene copy number level by FISH and at the protein
expression level by IHC in FFPE tissue sections. Patient subgroups defined using varying cutoff
values for gene copy number or amplification ratios, or by protein expression levels, were
evaluated for clinical outcome (PD or SD) to identify possible correlations. Results show a
trend toward higher proportions of SD patients than PD patients belonging to the subgroups
defined by the highest cutoff values for gene copy number or protein expression levels, but this
exploratory result requires independent confirmation.
Phospho-HER3 was examined as a potential pharmacodynamic and tissue biomarker; however,
research using tissue microarrays indicated that the phospho-HER3 epitope is not stable in
archived tissue, and fresh tissue could not be examined because patients were not prospectively
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
14
biopsied. Attempts to assay the HER3 ligand heregulin by either IHC or quantitative
polymerase chain reaction are still ongoing.
DISCUSSION
This first-in-human study of U3-1287, a first-in-class HER3-targeted fully human monoclonal
antibody, supports dosing regimens at a range of 9 to 20 mg/kg U3-1287 q2w or q3w. U3-1287
exhibited a favorable safety profile and preliminary evidence of antitumor activity.
The most frequently reported AEs included fatigue, diarrhea, nausea, and dyspnea. This small
patient cohort did not provide clear evidence of a dose-dependent relationship for toxicity. Most
incidences of U3-1287–related events were mild to moderate (grades 1 or 2). There were no
grade 4 or 5 AEs related to U3-1287, and no treatment discontinuations were attributed to a U3-
1287–related AE.
The development of neutralizing antibodies against therapeutic monoclonal antibodies in a
patient can lead to the loss of efficacy or to more serious clinical effects. As U3-1287 is a fully
human antibody, immunogenicity was not expected to be a concern, and, consistent with this,
no neutralizing anti–U3-1287 antibodies were detected in this patient population following
exposure to U3-1287. PK results and simulations from q2w dosing suggest that doses 9 mg/kg
q3w and above achieve steady state trough levels 10-fold in excess of those corresponding to
maximal efficacy in mice. Preclinical experiments showed a correlation between trough
concentrations and pharmacodynamics, as assessed by reductions in phospho-HER3 levels (see
Supplementary Fig. S2). Variation of treatment schedule around a constant dose suggested that
trough levels are more important to pharmacodynamics than peak levels in the murine system.
However, a number of factors affecting the ability of an antibody to penetrate solid tumors (e.g.,
variable intervessel distances and high interstitial pressure [31]) may be less prominent in the
smaller tumors of mice. Therefore, the results from murine studies cannot be directly translated
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
15
into recommended dose levels for humans, and, thus, 9 mg/kg q3w may be viewed as the
minimal dose level needed to achieve a significantly higher concentration in humans than is
required in murine systems. U3-1287 has demonstrated an acceptable safety profile in doses up
to 20 mg/kg q2w; therefore, it is recommended that doses of 9 to 20 mg/kg q2w or q3w be used
for collecting further safety, efficacy, and biodistribution data. Ongoing clinical studies are
utilizing U3-1287 q3w dosing regimens for enhanced patient convenience. While
pharmacodynamic activity could not be effectively assessed in this study to confirm dose
selection, 2 independent studies are in progress to refine dose selection: a radiolabeled
biodistribution study and a dose-ranging phase I/II study in combination with erlotinib, another
HER family inhibitor.
HER3 has been shown to be a major activator of phosphatidylinositol 3-kinase/Akt signaling in
EGFR-addicted and HER2-amplified cancers.(11,32,33) Previous studies have correlated
elevated HER3 expression with poor prognosis in a number of tumor types.(12–16) There was a
trend in this patient population toward the association of clinical benefit with high levels of
HER3 amplification or expression. However, due to the large number of exploratory
comparisons, independent confirmation is required. This association was not sufficient to allow
patient stratification and needs further examination in additional studies, including in more
homogeneous populations and in the context of combination therapy. Total HER3 expression
might also be considered for incorporation into a multicomponent classifier for patient selection
in the future. Assays to look at pathway activation and presence of ligand, rather than simple
receptor expression, are under development but remain a challenge in archived tissues.
Early evidence of clinical activity for U3-1287 in a selected population was suggested by
several patients with prolonged SD and/or metabolic responses. It has been suggested that
activated HER3 plays a role in the development of resistance to HER2 and EGFR inhibitors and
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
16
that the use of a HER3 inhibitor, such as U3-1287, may prevent or overcome such resistance if
used in combination with these agents. The safety and PK profile of U3-1287 monotherapy in
this population favors future studies of this agent in combination regimens, particularly with
anti-EGFR– and anti-HER2–based therapies used in colorectal, head and neck, and breast
cancers.(18,34,35) A phase I/II trial is ongoing to examine U3-1287 (9 or 18 mg/kg q3w) in
combination with erlotinib in NSCLC patients.
Acknowledgments
We would like to thank Xiaoping Jin and Erik Rasmussen for statistical support, Emily Liu for
clinical operational support, Alin Chen for pharmacokinetic calculations, Daniel Freeman and
Jeanne Mendell-Harary for advice on pharmacokinetic and pharmacodynamic issues, and
Cheryl Chun (BlueMomentum) for medical writing assistance. Funding for medical writing
support was provided by Daiichi Sankyo.
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
17
REFERENCES
1. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of
the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000;77:25–
79.
2. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu
Rev Biochem 1987;56:881–914.
3. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: Signal
diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997;410:83–
6.
4. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, et al. The ErbB-
2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for
multiple stroma-derived growth factors. Proc Natl Acad Sci U S A 1999;96:4995–5000.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al.
Activating mutations in the epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39.
6. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models
of ERBB2-induced breast cancer. Nat Rev Cancer 2007;7:389–97.
7. Moasser MM. The oncogene HER2: Its signaling and transforming functions and its role in
human cancer pathogenesis. Oncogene 2007;26:6469–87.
8. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-
family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature
2007;445:437–41.
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
18
9. Jain A, Penuel E, Mink S, Schmidt J, Hodge A, Favero K,et al: HER kinase axis receptor
dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite
failure to block cellular proliferation. Cancer Res 2010;70:1989–99.
10. Wang S, Huang X, Lee CK, Liu B. Elevated expression of erbB3 confers paclitaxel
resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Oncogene 2010;29:4225–36.
11. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET
amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Science 2007;316:1039–43.
12. Bièche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R. Prognostic value of ERBB
family mRNA expression in breast carcinomas. Int J Cancer 2003;106:758–65.
13. Müller-Tidow C, Diederichs S, Bulk E, Pohle T, Steffen B, Schwable J, et al. Identification
of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. Cancer Res
2005;65:1778–82.
14. Yi ES, Harclerode D, Gondo M, Stephenson M, Brown RW, Younes M, et al. High c-erbB-
3 protein expression is associated with shorter survival in advanced non-small cell lung
carcinomas. Mod Pathol 1997;10:142–8.
15. Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, et al. ErbB-3
predicts survival in ovarian cancer. J Clin Oncol 2006;24:4317–23.
16. Beji A, Horst D, Engel J, Kirchner T, Ullrich A. Toward the prognostic significance and
therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer
Res 2012;18:956–968.
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
19
17. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy.
Cancer Gene Ther 2008;15:413–48.
18. Wilson TR, Lee DY, Berry L, Shames DS, Settleman J. Neuregulin-1-mediated autocrine
signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.
Cancer Cell 2011;20:158–72.
19. Sheng Q, Liu X, Fleming E, Yuan K, Piao H, Chen J, et al. An activated ErbB3/NRG1
autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell
2010;17:298–310.
20. Zhou BB, Peyton M, He B, Liu C, Girard L, Caudler E, et al. Targeting ADAM-mediated
ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer
Cell 2006;10:39–50.
21. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL 3rd. Insect cell-expressed
p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A
1994;91:8132–6.
22. Gullick WJ. The c-erbB3/HER3 receptor in human cancer. Cancer Surv 1996;27:339–49.
23. Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Allroy I, Klapper L, et al.
Diversification of Neu differentiation factor and epidermal growth factor signaling by
combinatorial receptor interactions. EMBO J 1996;15:2452–67.
24. Treder M, Hartmann S, Ogbagabriel S, Borges E, Green L, Kang J, et al. Fully human anti-
HER3 monoclonal antibodies (mAbs) inhibit oncogenic signaling and tumor cell growth in
vitro and in vivo. Presented at American Association for Cancer Research Annual Meeting;
April 12,16, 2008; San Diego, CA [abstract LB-20].
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
20
25. Freeman D, Ogbagabriel S, Rothe M, Radinsky R, Treder M. Fully human anti-HER3
monoclonal antibodies (mAbs) have unique in vitro and in vivo functional and antitumor
activities versus other HER family inhibitors. Presented at American Association for Cancer
Research Annual Meeting; April 12,16, 2008; San Diego, CA [abstract LB-21].
26. Treder M, Ogbagabriel S, Moor R, Schulze-Horsel U, Hettmann T, Rothe M, et al. Fully
human anti-HER3 mAb U3-1287 (AMG 888) demonstrates unique in vitro and in vivo
activities versus other HER family inhibitors in NSCLC models. Eur J Cancer
2008;6(suppl):99[abstract 309].
27. Freeman DJ, Ogbagabriel S, Bready J, Sun J-K, Radisnky R, Hettmann T. U3–1287 (AMG
888), a fully human anti-HER3 mAb, demonstrates in vitro and in vivo efficacy in the FaDu
model of human squamous cell carcinoma of the head and neck (SCCHN). Mol Cancer Ther
2011;10 (suppl 1):[abstract A182].
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New
guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst
2000;92:205–16.
29. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al.
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose
and positron emission tomography: Review and 1999 EORTC recommendations. Eur J
Cancer 1999;35:1773–82.
30. Lum P, Perez Ruixo JJ, Ogbagabriel S, Doshi S, Chen A, Yang BB, et al. Identifying first in
human (FIH) doses and schedule of U3-1287 (AMG 888), a fully human anti-HER3 mAb,
based on preclinical pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. Mol
Cancer Ther 2009;8 (suppl 1):[abstract B167].
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
21
31. Beckman RA, Weiner LM, Davis HM. Antibody constructs in cancer therapy: protein
engineering strategies to improve exposure in solid tumors. Cancer 2007;109:170–9.
32. Engelman JA, Jänne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, et al. ErbB-3
mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer
cell lines. Proc Natl Acad Sci U S A 2005;102:3788–93.
33. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-
target HER3. Br J Cancer 2007;97:453–7.
34. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation
of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody
cetuximab. Sci Transl Med 2011;3:99ra86.
35. Grøvdal LM, Kim J, Holst MR, Knudsen SL, Grandal MV, van Deurs B. EGF receptor
inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells. Cell Signal
2012;24:296–301.
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
22
Table 1. Patient demographics and characteristics
Characteristic Dose-escalation
study (n = 26)
Dose-expansion
study (n = 31)
Total (N = 57)
Sex, n (%)
Male 19 (73.1) 13 (41.9) 32 (56.1)
Female 7 (26.9) 18 (58.1) 25 (43.9)
Age, y
Median (range) 56.5 (39–75) 62.0 (39–80) 60.0 (39–80)
ECOG score, n (%)
0 5 (19.2) 13 (41.9) 18 (31.6)
1 19 (73.1) 17 (54.8) 36 (63.2)
2 2 (7.7) 1 (3.2) 3 (5.3)
Prior chemotherapy, n (%) 26 (100) 31 (100) 57 (100)
Median number (range) 5.5 (2–13) 5.0 (2–10) 5.0 (2–13)
Prior EGFR-baseda, n (%) 16 (61.5) 25 (80.6) 41 (71.9)
Prior HER2-baseda, n (%) 1 (3.8) 1 (3.2) 2 (3.5)
Prior radiotherapy, n (%) 13 (50) 15 (48.4) 28 (49.1)
Tumor type, n (%)
Head and neck 0 1 (3.2) 1 (1.8)
Breast 3 (11.5) 1 (3.2) 4 (7.0)
Ovary 1 (3.8) 1 (3.2) 2 (3.5)
Lung
NSCLC 3 (11.5) 17 (54.8) 20 (35.1)
SCLC 1 (3.8) 0 1 (1.8)
Colorectal 18 (69.2) 11 (35.5) 29 (50.9)
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
23
Years since metastatic diagnosis,
median (range)
2.61 (0.2–7.3) 3.50 (0.5–7.4) 2.69 (0.2–7.4)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor
receptor; HER2, human epidermal growth factor receptor 2; NSCLC, non–small cell lung
cancer; SCLC, small cell lung cancer.
a Prior lapatinib therapy (2 patients) is represented in both prior EGFR- and prior HER2-based
categories.
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
24
Table 2. Treatment-emergent adverse events (AEs) in > 5% of patients
AE, n (%) All AEs U3-1287-related AEs
All grades, n
(%)
Grade ≥ 3, n
(%)
All grades, n
(%)
Grade ≥ 3, n
(%)
All AEs 55 (96.5) 28 (49.1) 26 (45.6) 1 (1.8)a
Fatigue 24 (42.1) 0 12 (21.1) 0
Diarrhea 14 (24.6) 0 7 (12.3) 0
Nausea 13 (22.8) 1 (1.8) 6 (10.5) 0
Dyspnea 12 (21.1) 2 (3.5) 0 0
Back pain 10 (17.5) 1 (1.8) 0 0
Decreased appetite 10 (17.5) 0 4 (7.0) 0
Cough 9 (15.8) 0 0 0
Constipation 8 (14.0) 1 (1.8) 2 (3.5) 0
Anemia 7 (12.3) 2 (3.5) 0
Hypokalemia 7 (12.3) 3 (5.3) 1 (1.8) 0
Vomiting 7 (12.3) 0 2 (3.5) 0
Anxiety 6 (10.5) 0 0 0
Alanine aminotransferase
increased
5 (8.8) 0 1 (1.8) 0
Aspartate aminotransferase
increased
5 (8.8) 0 1 (1.8) 0
Blood alkaline phosphatase
increased
5 (8.8) 2 (3.5) 2 (3.5) 0
Dizziness 5 (8.8) 1 (1.8) 0 0
Dysgeusia 5 (8.8) 0 3 (5.3) 0
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
25
Dyspepsia 5 (8.8) 0 0 0
Edema peripheral 5 (8.8) 0 0 0
Musculoskeletal chest pain 5 (8.8) 1 (1.8) 0 0
Pleural effusion 5 (8.8) 2 (3.5) 0 0
Abdominal pain 4 (7.0) 0 0 0
Activated partial
thromboplastin time
4 (7.0) 2 (3.5) 2 (3.5) 0
Cancer pain 4 (7.0) 1 (1.8) 0 0
Epistaxis 4 (7.0) 0 0 0
Hematuria 4 (7.0) 0 1 (1.8) 0
Hyperhidrosis 4 (7.0) 0 1 (1.8) 0
Hyponatremia 4 (7.0) 2 (3.5) 1 (1.8) 1 (1.8)
Insomnia 4 (7.0) 0 0 0
Musculoskeletal pain 4 (7.0) 2 (3.5) 0 0
Oropharyngeal pain 4 (7.0) 0 0 0
Pruritus 4 (7.0) 0 1 (1.8) 0
Abdominal pain upper 3 (5.3) 0 0 0
Arthralgia 3 (5.3) 1 (1.8) 0 0
Dehydration 3 (5.3) 0 0 0
Depression 3 (5.3) 0 0 0
Dyspnea exertional 3 (5.3) 0 0 0
Headache 3 (5.3) 0 0 0
Hyperglycemia 3 (5.3) 0 0 0
Hypertension 3 (5.3) 0 0 0
Hypomagnesemia 3 (5.3) 0 0 0
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
26
Lymphopenia 3 (5.3) 1 (1.8) 1 (1.8) 0
Oral candidiasis 3 (5.3) 0 1 (1.8) 0
Pain in extremity 3 (5.3) 0 0 0
Peripheral sensory
neuropathy
3 (5.3) 0 2 (3.5) 0
Pyrexia 3 (5.3) 0 0 0
Rash 3 (5.3) 1 (1.8) 1 (1.8) 0
Stomatitis 3 (5.3) 0 2 (3.5) 0
Urinary tract infection 3 (5.3) 0 0 0
Weight decreased 3 (5.3) 0 0 0
aOne patient experienced a nonserious grade 3 event of hyponatremia and a nonserious grade 3
event of hypophosphatemia.
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
27
Table 3. PK parameters after IV infusion of U3-1287
Cohort
1
(0.3 mg/kg)
2
(1 mg/kg)
3
(3 mg/kg)
4
(6 mg/kg)
5
(9 mg/kg)
6
(14 mg/kg)
7
(20 mg/kg)
N 3 3 5 4 4 4 3
AUC, µg·day/mL
N 3 3 4 4 4 3a 3
Mean 11.56 59.65 380.36 784.34 1255.89 1433.95d 2512.68
SD 5.64 4.97 148.36 93.14 151.55 692.60 402.8
Median 9.27 62.17 364.43 748.65 1261.74 1534.52 2682.09
tmax, h
N 3 3 5 4 4 4 3
Median 1.08 1.08 4.32 1.13 2.79 1.00 3.83
Range 1.05–6.83 0.92–7.00 1.10–7.00 1.00–4.07 1.08–24.92 1.00–1.02 1.07–6.63
Cmax, µg/mL
N 3 3 5 4 4 4 3
Research.
on January 20, 2020. © 2013 A
merican A
ssociation for Cancer
clincancerres.aacrjournals.org D
ownloaded from
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author M
anuscript Published O
nlineFirst on A
pril 16, 2013; DO
I: 10.1158/1078-0432.CC
R-12-3051
28
Mean 6.11 20.90 66.44 162.75 243.50 302.25 422.00
SD 1.30 3.30 15.43 52.22 33.31 37.70 19.00
Median 5.92 22.50 61.90 164.00 251.00 312.50 427.00
Cmin, µg/mL
N 3 2 4 4 4 2b,c 2
Mean 0 0 3.99 8.37 5.14 20.81 36.00
SD 0 0 2.64 5.99 8.60 19.78 3.82
Median 0 0 4.08 9.64 1.32 20.81 36.00
t1/2, d
N NR NR 5 4 4 3c 2e
Mean NR NR 5.51 8.36 7.67 7.95 8.90
SD NR NR 1.62 1.10 3.21 2.91 1.30
Median NR NR 6.52 8.35 7.82 6.74 8.90
Research.
on January 20, 2020. © 2013 A
merican A
ssociation for Cancer
clincancerres.aacrjournals.org D
ownloaded from
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author M
anuscript Published O
nlineFirst on A
pril 16, 2013; DO
I: 10.1158/1078-0432.CC
R-12-3051
29
Abbreviations: AUC, area under the serum concentration time curve; Cmax, maximum observed serum concentration; Cmin, minimum observed
serum concentration after the end of infusion; IV, intravenous; NR, not relevant; PK, pharmacokinetic; SD, standard deviation; t1/2, serum
terminal half-life; tmax, time to maximum concentration.
aAUC excluded 1 subject as at least 2 PK samples at terminal phase were excluded or not collected.
bCmin excluded for 1 subject for sampling-related deviations.
cNo data for 1 subject.
dOne patient from cohort 6 had a higher clearance (AUC = 696.559 µg·day/mL) than the median clearance from all dose cohorts receiving 6
mg/kg or more.
et1/2 excluded for 1 subject as R2 was < 0.8.
Research.
on January 20, 2020. © 2013 A
merican A
ssociation for Cancer
clincancerres.aacrjournals.org D
ownloaded from
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author M
anuscript Published O
nlineFirst on A
pril 16, 2013; DO
I: 10.1158/1078-0432.CC
R-12-3051
30
FIGURE LEGENDS
Fig 1. U3-1287 pharmacokinetics of 9–20 mg/kg cohorts from part 2. Peak (closed symbols) and trough (open symbols) concentrations at 9
mg/kg (red symbols), 14 mg/kg (orange symbols), and 20 mg/kg (green symbols). Lower horizontal red line is the trough corresponding to
maximal efficacy (IC90) in mice; upper horizontal red line is 10-times this value, the minimal target trough concentration for humans. All 3 doses
achieve trough above the human target; higher doses achieve this in all patients sooner, averaging even higher levels.
Fig 2. SD duration for all subjects with SD per modified RECIST at the earliest observation time point. If a subject discontinued, died, or was
lost to follow-up with no documentation of progressive disease, duration of SD was censored at the date of last tumor assessment.
Fig 3. Computed tomography scan in a patient with non–small cell lung cancer, treated with 20 mg/kg U3-1287. (A) Screening (SCR). (B) Week
18. (C) Changes in sum of longest diameters (SLD) while on treatment with U3-1287.
Research.
on January 20, 2020. © 2013 A
merican A
ssociation for Cancer
clincancerres.aacrjournals.org D
ownloaded from
Author m
anuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author M
anuscript Published O
nlineFirst on A
pril 16, 2013; DO
I: 10.1158/1078-0432.CC
R-12-3051
Figure 1
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
Figure 2
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
Figure 3
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051
Published OnlineFirst April 16, 2013.Clin Cancer Res Patricia M. LoRusso, Pasi A. Janne, Moacyr Ribeiro de Oliveira, et al. Antibody, in Patients With Advanced Solid TumorsPhase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal
Updated version
10.1158/1078-0432.CCR-12-3051doi:
Access the most recent version of this article at:
Material
Supplementary
http://clincancerres.aacrjournals.org/content/suppl/2013/05/06/1078-0432.CCR-12-3051.DC1
Access the most recent supplemental material at:
Manuscript
Authoredited. Author manuscripts have been peer reviewed and accepted for publication but have not yet been
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
Subscriptions
Reprints and
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/early/2013/04/16/1078-0432.CCR-12-3051To request permission to re-use all or part of this article, use this link
Research. on January 20, 2020. © 2013 American Association for Cancerclincancerres.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on April 16, 2013; DOI: 10.1158/1078-0432.CCR-12-3051